Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

Blanca XicoyClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain

Josep-Maria RiberaClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, SpainCorrespondence[email protected]

Markus MüllerDepartment of Internal Medicine, Vivantes Klinikum Neukölln, Berlin, Germany

Olga GarcíaClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain

Christian HoffmannICH Study Center, Hamburg/University of Schleswig Holstein, Campus Kiel, Germany

Albert OriolClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain

Marcus HentrichDepartment of Hematology and Oncology, Hospital Harlaching, Munich, Germany

Carlos GrandeHematology Department, Hospital Doce de Octubre, Madrid, Spain

Jan-Christian WasmuthDepartment of Internal Medicine I, University of Bonn, Germany

Jordi EsteveHematology Department, Hospital Clínic, Barcelona, Spain

Jan van LunzenDepartment of Internal Medicine, University of Hamburg-Eppendorf, Hamburg, Germany

Eloy del PotroHematology Department, Hospital Clínico San Carlos, Madrid, Spain

Heribert Knechten PZB, Aachen, Germany

Salut BrunetHematology Department, Hospital de Sant Pau, Barcelona, Spain

Christoph MayrÄrzteforum Seestrasse, Berlin, Germany

Lourdes EscodaHematology Department, Hospital Joan XXIII, Tarragona, Spain

Philipp SchommersFirst Department of Internal Medicine, University of Cologne, Cologne, Germany

Natalia AlonsoHematology Department, Hospital Xeral de Santiago de Compostela, Spain

Ferran Vall-lloveraHematology Department, Hospital Mutua de Terrassa, Spain

Montserrat PérezHematology Department, Hospital Virgen de la Concha, Zamora, Spain

Mireia MorgadesClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain

José GonzálezHematology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain

Angeles FernándezHematology Department, Hospital Xeral-CIES, Vigo, Spain

Jan ThodenDepartment of Internal Medicine, University Hospital of Freiburg, Germany

Nicola GökbugetDepartment of Hematology, Goethe University Hospital, Department of Medicine II, Frankfurt, Germany

Dieter HoelzerDepartment of Hematology, Goethe University Hospital, Department of Medicine II, Frankfurt, Germany

Gerd FätkenheuerFirst Department of Internal Medicine, University of Cologne, Cologne, Germany

Christoph WyenFirst Department of Internal Medicine, University of Cologne, Cologne, Germany

& for the PETHEMA Group and German HIV Lymphoma Cohort show all

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

Supplementary Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date